These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 33007432)

  • 1. Immunotherapy for advanced hepatocellular carcinoma, where are we?
    Zhang L; Ding J; Li HY; Wang ZH; Wu J
    Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188441. PubMed ID: 33007432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
    Liu Z; Lin Y; Zhang J; Zhang Y; Li Y; Liu Z; Li Q; Luo M; Liang R; Ye J
    J Exp Clin Cancer Res; 2019 Nov; 38(1):447. PubMed ID: 31684985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular therapies for HCC: Looking outside the box.
    Faivre S; Rimassa L; Finn RS
    J Hepatol; 2020 Feb; 72(2):342-352. PubMed ID: 31954496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model.
    Kimura T; Kato Y; Ozawa Y; Kodama K; Ito J; Ichikawa K; Yamada K; Hori Y; Tabata K; Takase K; Matsui J; Funahashi Y; Nomoto K
    Cancer Sci; 2018 Dec; 109(12):3993-4002. PubMed ID: 30447042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy.
    Lin YY; Tan CT; Chen CW; Ou DL; Cheng AL; Hsu C
    Semin Liver Dis; 2018 Nov; 38(4):379-388. PubMed ID: 30357775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
    Chen Y; Ramjiawan RR; Reiberger T; Ng MR; Hato T; Huang Y; Ochiai H; Kitahara S; Unan EC; Reddy TP; Fan C; Huang P; Bardeesy N; Zhu AX; Jain RK; Duda DG
    Hepatology; 2015 May; 61(5):1591-602. PubMed ID: 25529917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma.
    Uson Junior PLS; Liu AJ; Sonbol MB; Borad MJ; Bekaii-Saab TS
    Chin Clin Oncol; 2021 Feb; 10(1):11. PubMed ID: 33541088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-immunotherapy options for the first-line management of hepatocellular carcinoma: exploring the evolving role of sorafenib and lenvatinib in advanced disease.
    Perera S; Kelly D; O'Kane GM
    Curr Oncol; 2020 Nov; 27(Suppl 3):S165-S172. PubMed ID: 33343210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody.
    Liu G; Zhou W; Li X; Guo L; He T; Zhao J; Gong L
    Front Immunol; 2021; 12():712351. PubMed ID: 34504494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials.
    Kudo M
    Oncology; 2017; 92 Suppl 1():50-62. PubMed ID: 28147363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent developments with immunotherapy for hepatocellular carcinoma.
    Waidmann O
    Expert Opin Biol Ther; 2018 Aug; 18(8):905-910. PubMed ID: 29995439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma.
    Catalano M; Casadei-Gardini A; Vannini G; Campani C; Marra F; Mini E; Roviello G
    Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1353-1365. PubMed ID: 34289756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combinatorial immunotherapy of sorafenib and blockade of programmed death-ligand 1 induces effective natural killer cell responses against hepatocellular carcinoma.
    Wang Y; Li H; Liang Q; Liu B; Mei X; Ma Y
    Tumour Biol; 2015 Mar; 36(3):1561-6. PubMed ID: 25371070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy.
    Zhao Y; Zhang YN; Wang KT; Chen L
    Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188391. PubMed ID: 32659252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenvatinib: a potential breakthrough in advanced hepatocellular carcinoma?
    Oikonomopoulos G; Aravind P; Sarker D
    Future Oncol; 2016 Feb; 12(4):465-76. PubMed ID: 26785762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for hepatocellular carcinoma: Recent advances and future targets.
    Yu SJ
    Pharmacol Ther; 2023 Apr; 244():108387. PubMed ID: 36948423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
    Longo V; Brunetti O; Gnoni A; Licchetta A; Delcuratolo S; Memeo R; Solimando AG; Argentiero A
    Medicina (Kaunas); 2019 Oct; 55(10):. PubMed ID: 31627433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoptive cell transfer therapy for hepatocellular carcinoma.
    Zhang R; Zhang Z; Liu Z; Wei D; Wu X; Bian H; Chen Z
    Front Med; 2019 Feb; 13(1):3-11. PubMed ID: 30659408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma.
    Dal Bo M; De Mattia E; Baboci L; Mezzalira S; Cecchin E; Assaraf YG; Toffoli G
    Drug Resist Updat; 2020 Jul; 51():100702. PubMed ID: 32371296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunostimulatory monoclonal antibodies for hepatocellular carcinoma therapy. Trends and perspectives.
    Mazzolini GD; Malvicini M
    Medicina (B Aires); 2018; 78(1):29-32. PubMed ID: 29360073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.